## RECEIVED

NOV 2 0 2007

Intarcia Dkt No. ALD 047.10 USSN: 10/814,801 PATENT

**CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)** I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated. Date of Transmittal

| In Re Application of: DIONNE, Keith E., et al. | Confirmation No.: 4974   |
|--|--------------------------|
| Serial No.: 10/814,801                         | Art Unit: 1615           |
| Filing Date: 31 March 2004                     | Examiner: Kennedy, S. E. |

## REVOCATION AND SUBSTITUTE POWER OF ATTORNEY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned has reviewed all the documents in the chain of title pursuant to 37 C.F.R. §3.73, and to the best of the undersigned's knowledge, Intercia Therapeutics, Inc., is the assignee of the entire right, title, and interest in this application, specifically: the assignment recorded on 12/17/2004 at Reel/Frame 016078/0539, and the assignment recorded on 10/26/2007 at Reel/Frame 020035/0441.

Intarcia Therapeutics, Inc., hereby revokes all powers of attorney previously given and hereby appoints the following attorney and agent to prosecute this application and to make alterations and amendments therein. Each of the following attorney and agent has full power of substitution and revocation:

Barbara G. McClung (Registration No. 33,113) Gary R. Fabian (Registration No. 33,875)

Intarcia Dkt No. ALD 047.10

USSN: 10/814,801

PATENT

Please direct all future correspondences in connection with this application to:

Customer Number: 000074866

Barbara G. McClung, Esq.
Vice President, General Counsel and Corporate Secretary
Intarcia Therapeutics, Inc.
2000 Powell Street
Suite 1640
Emeryville, CA 94608

Phone: (510) 652-2600 Fax: (510) 652-2657

No fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 504212 (please reference docket number ALD 047.10) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

1/14/0-1

Barbara G. McClung, Esq.

Respectfully submitted,

Vice President, General Counsel and

Corporate Secretary Intarcia Therapeutics, Inc. Registration No. 33,113

Intarcia Therapeutics, Inc. 2000 Powell Street

Suite 1640

Emeryville, CA 94608

Phone: (510) 652-2600 Fax: (510) 652-2657